AT

Renal Tubular Disorders

Medicine · Nephrology · lean revision notes

Renal Tubular Disorders

Renal tubular disorders are inherited or acquired defects in tubular transport that produce characteristic electrolyte and acid-base disturbances without significant loss of glomerular filtration. They are a perennial NEET PG favourite because each syndrome has a clean, pattern-based "signature" — a specific acidosis or alkalosis, a potassium derangement, and a diagnostic test (urine anion gap, urine pH, plasma renin/aldosterone). Master the patterns and these become free marks.

Orientation: the two big families

Tubular disorders split conceptually into acid-base defects (the renal tubular acidoses, RTA — types I, II, IV) and salt-wasting / salt-retaining channelopathies (Bartter, Gitelman, Liddle). The RTAs cause a normal anion gap (hyperchloraemic) metabolic acidosis; the channelopathies mostly cause a metabolic alkalosis (except Liddle, which is the salt-retaining odd one out).

High-yield: RTA = normal anion gap (hyperchloraemic) metabolic acidosis. Bartter/Gitelman = hypokalaemic metabolic alkalosis that mimics chronic loop/thiazide diuretic use. Liddle = hypertension + hypokalaemic alkalosis with low renin and low aldosterone.


Renal Tubular Acidosis (RTA) — classification

RTA is a group of disorders where the kidney fails to either reabsorb filtered bicarbonate (proximal/type II) or excrete the daily acid load (distal/type I and type IV), producing a non-anion-gap metabolic acidosis with a normal or near-normal GFR.

Feature Type I (Distal) Type II (Proximal) Type IV (Hyperkalaemic)
Primary defect Failure of H⁺ secretion in distal tubule (α-intercalated cell) Failure of HCO₃⁻ reabsorption in proximal tubule Aldosterone deficiency / resistance
Serum K⁺ Low (hypokalaemia) Low / low-normal High (hyperkalaemia)
Urine pH > 5.5 (cannot acidify) Variable: > 5.5 when above threshold, < 5.5 once HCO₃⁻ depleted Usually < 5.5
Plasma HCO₃⁻ (untreated) Can be very low (< 10) Moderate (12–18) Mild (> 17)
Urine anion gap Positive Positive (variable) Positive
Stones / nephrocalcinosis Yes (calcium phosphate) No (rather, rickets/osteomalacia) No
Fanconi syndrome No Yes (when generalised) No
Alkali dose needed Low (1–2 mEq/kg/day) High (10–15 mEq/kg/day) Low + manage K⁺

High-yield: The single most discriminating bedside value — urine pH > 5.5 in the face of systemic acidosis = distal (type I) RTA. A patient who can drop urine pH below 5.5 has an intact distal acidification mechanism.

Why there is no "Type III"

Type III RTA is a largely obsolete term describing a mixed proximal + distal picture, classically seen in carbonic anhydrase II deficiency (osteopetrosis with RTA and cerebral calcification). It is rarely tested except as a "which type does not exist as a standalone clinical entity" trick.


Type I — Distal RTA

Pathophysiology

The α-intercalated cells of the cortical collecting duct fail to secrete H⁺ (defective H⁺-ATPase, H⁺/K⁺-ATPase, or the basolateral Cl⁻/HCO₃⁻ exchanger AE1/band 3). The kidney therefore cannot lower urine pH below ~5.5 even when the body is profoundly acidotic. Failure to excrete acid → progressive metabolic acidosis; the resulting hypercalciuria and high urine pH precipitate calcium phosphate stones and nephrocalcinosis.

Causes (think: anything that injures the distal nephron)

  • Hereditary: AE1, H⁺-ATPase mutations (some with sensorineural deafness).
  • Autoimmune: Sjögren syndrome (classic), SLE, rheumatoid arthritis.
  • Drugs/toxins: amphotericin B (the prototype — punches holes in the luminal membrane), lithium, ifosfamide.
  • Hypercalciuria / medullary sponge kidney, chronic obstruction.

Clinical features

  • Children: failure to thrive, rickets, polyuria, recurrent stones.
  • Adults: muscle weakness from hypokalaemia (may be severe enough to cause paralysis or arrhythmia), bone pain, recurrent calcium phosphate calculi, nephrocalcinosis.

Diagnosis

  • Normal anion gap metabolic acidosis + hypokalaemia + urine pH > 5.5 + positive urine anion gap.
  • Confirmatory: ammonium chloride (acid) loading test — fails to acidify urine below pH 5.5. (Furosemide/fludrocortisone test is a modern alternative.)

Management

  • Oral alkali — potassium citrate is preferred (corrects both acidosis and hypokalaemia and reduces stone formation); 1–2 mEq/kg/day. Sodium bicarbonate is an alternative but can worsen hypokalaemia.

High-yield: Distal RTA → hypokalaemia + nephrocalcinosis + calcium phosphate stones. Amphotericin B and Sjögren syndrome are the two most-asked causes.


Type II — Proximal RTA

Pathophysiology

The proximal tubule cannot reabsorb the filtered HCO₃⁻ load (defective Na⁺/H⁺ exchanger NHE3, basolateral Na⁺/HCO₃⁻ cotransporter NBCe1, or carbonic anhydrase). Bicarbonate spills into the urine until plasma HCO₃⁻ falls to a new lower threshold (~15 mEq/L), at which point the reduced filtered load can finally be reabsorbed and a new steady state is reached. This is why proximal RTA is self-limiting in severity and rarely causes HCO₃⁻ below ~12.

A key teaching point: once the plasma bicarbonate falls below threshold, the distal nephron is intact, so the patient can acidify urine to pH < 5.5. But when treated with alkali (pushing plasma HCO₃⁻ above threshold), bicarbonaturia resumes and urine pH rises — hence the "variable urine pH."

Fanconi syndrome

When the proximal defect is generalised, it causes the Fanconi syndrome: a global proximal reabsorptive failure with:

  • Glycosuria (with normal blood glucose)
  • Phosphaturia → hypophosphataemia → osteomalacia / rickets
  • Aminoaciduria
  • Uricosuria, proximal RTA (bicarbonaturia)

High-yield: Proximal RTA + glycosuria + phosphaturia + aminoaciduria = Fanconi syndrome. Bone disease (rickets/osteomalacia) dominates, not stones.

Causes

  • Children: cystinosis (commonest inherited cause of Fanconi syndrome), Wilson disease, galactosaemia, hereditary fructose intolerance, Lowe syndrome, tyrosinaemia.
  • Acquired: multiple myeloma (light chains), tenofovir, ifosfamide, acetazolamide (carbonic anhydrase inhibitor — pure proximal RTA), heavy metals (lead, cadmium, mercury), aminoglycosides, valproate, expired tetracyclines, amyloidosis.

Management

  • Requires large doses of alkali (10–15 mEq/kg/day) because much is lost in urine; potassium citrate preferred.
  • Thiazides can be used (induce mild volume contraction → enhances proximal HCO₃⁻ reabsorption); add phosphate and vitamin D for bone disease.

High-yield: Tenofovir, multiple myeloma, cystinosis (kids) and acetazolamide are the exam's go-to causes of proximal RTA / Fanconi.


Type IV — Hyperkalaemic RTA

Pathophysiology

The unifying mechanism is aldosterone deficiency or aldosterone resistance, reducing distal Na⁺ reabsorption and K⁺/H⁺ secretion. The resulting hyperkalaemia further impairs renal ammoniagenesis, reducing acid excretion → mild non-anion-gap acidosis. Unlike type I, the distal H⁺-ATPase still works, so urine pH is usually < 5.5, but acid excretion is inadequate because of the hyperkalaemia and low ammonium.

Causes

  • Diabetic nephropathy with hyporeninaemic hypoaldosteronism (the single commonest cause).
  • Drugs: ACE inhibitors/ARBs, spironolactone/eplerenone, amiloride, triamterene, trimethoprim, NSAIDs, heparin, calcineurin inhibitors (ciclosporin, tacrolimus).
  • Addison's disease (primary adrenal insufficiency), congenital adrenal hyperplasia.
  • Obstructive uropathy, sickle cell nephropathy (aldosterone resistance).

Management

  • Fludrocortisone (mineralocorticoid replacement) if hypoaldosteronism; loop diuretics and low-potassium diet to manage hyperkalaemia; stop offending drugs.

High-yield: Type IV is the only RTA with hyperkalaemia. Diabetic with mild hyperchloraemic acidosis + high K⁺ + urine pH < 5.5 = type IV RTA.


The urine anion gap (UAG) — the key investigation

The UAG is a surrogate for urinary ammonium (NH₄⁺) excretion, helping distinguish renal from GI (extra-renal) causes of a normal-anion-gap acidosis.

UAG = (Urine Na⁺ + Urine K⁺) − Urine Cl⁻

  • Negative UAG (< 0): high urinary NH₄⁺ → kidney is appropriately excreting acid → cause is extra-renal, classically diarrhoea (think "negative = GI loss, e.g. diarrhea"). Mnemonic: "neGUTive" — negative UAG points to the GUT.
  • Positive UAG (> 0): low urinary NH₄⁺ → kidney is failing to excrete acid → RTA (types I and IV both give a positive UAG).

High-yield: Diarrhoea → negative urine anion gap. RTA → positive urine anion gap. The mnemonic "neGUTive" (negative = GUT/diarrhoea) is the fastest recall.

Diagnostic flow for a normal-anion-gap metabolic acidosis

Confirm normal anion gap acidosisCheck serum K⁺ → if high think type IV → if low/normal, calculate urine anion gap → if negative → GI loss (diarrhoea); if positive → distal/proximal RTA → check urine pH: pH > 5.5 → type I; pH < 5.5 (or variable with high alkali requirement + glycosuria) → type II.


Bartter syndrome

A group of autosomal recessive defects in the thick ascending limb of the loop of Henle (TALH) — functionally equivalent to taking a loop diuretic (furosemide) continuously.

Mechanism & genetics

Mutations affect the NKCC2 cotransporter (type 1), ROMK potassium channel (type 2), ClC-Kb chloride channel (type 3), Barttin (type 4, with sensorineural deafness), or CaSR (type 5). Salt wasting → volume depletion → secondary hyperaldosteronism → renal K⁺ and H⁺ loss.

Features

  • Presents early (neonatal/childhood), often with polyhydramnios, failure to thrive.
  • Hypokalaemic metabolic alkalosis, salt wasting, normal-to-low blood pressure, high renin and high aldosterone.
  • Hypercalciuria → nephrocalcinosis (because the TALH normally drives passive calcium reabsorption).
  • Urinary calcium high; serum magnesium usually normal.

Gitelman syndrome

An autosomal recessive defect in the NCCT thiazide-sensitive Na⁺/Cl⁻ cotransporter of the distal convoluted tubule — functionally equivalent to chronic thiazide use. SLC12A3 mutation.

Features

  • Presents later (adolescence/adulthood), milder, often incidental.
  • Hypokalaemic metabolic alkalosis, normal/low BP, high renin/aldosterone — like Bartter — but:
  • Hypocalciuria (low urine calcium) and hypomagnesaemia — the two hallmark distinguishers.
  • Tetany, carpopedal spasm, chondrocalcinosis from magnesium loss.

Bartter vs Gitelman — the must-know comparison

Feature Bartter Gitelman
Tubular site Thick ascending limb Distal convoluted tubule
Mimics which diuretic Loop (furosemide) Thiazide
Age at presentation Neonatal / early childhood Adolescent / adult
Urine calcium High (hypercalciuria) Low (hypocalciuria)
Serum magnesium Usually normal Low (hypomagnesaemia)
Nephrocalcinosis Common Absent
Blood pressure Normal / low Normal / low
K⁺ / acid-base Low K⁺, metabolic alkalosis Low K⁺, metabolic alkalosis

High-yield: Both Bartter and Gitelman = hypokalaemic metabolic alkalosis with normal BP. Differentiate by urine calcium and serum magnesium: Bartter = hypercalciuria (loop-like); Gitelman = hypocalciuria + hypomagnesaemia (thiazide-like).

Management of Bartter/Gitelman

  • Potassium and magnesium replacement, liberal salt and fluid.
  • Potassium-sparing diuretics (spironolactone, amiloride) help retain K⁺.
  • Bartter: NSAIDs (indomethacin) reduce prostaglandin-driven salt wasting in the neonatal forms.

Liddle syndrome

The salt-retaining outlier — an autosomal dominant gain-of-function mutation of the epithelial sodium channel (ENaC) in the collecting duct (SCNN1B/SCNN1G). Constitutively active ENaC → excessive Na⁺ reabsorption and K⁺/H⁺ loss → "pseudohyperaldosteronism."

Features

  • Hypertension (early-onset) + hypokalaemic metabolic alkalosis.
  • Low renin AND low aldosterone — the channel is active independent of aldosterone.

Treatment

  • Amiloride or triamterene (directly block ENaC). Spironolactone does NOT work because the defect is downstream of the mineralocorticoid receptor — a classic NEET PG trick.

High-yield: Liddle = hypertension + hypokalaemia + low renin + low aldosterone, treated with amiloride (NOT spironolactone). Contrast with primary hyperaldosteronism (Conn): low renin but high aldosterone, responds to spironolactone.

Distinguishing the hypertensive low-renin states

Disorder Renin Aldosterone Treatment
Liddle syndrome Low Low Amiloride / triamterene
Primary hyperaldosteronism (Conn) Low High Spironolactone / surgery
Apparent mineralocorticoid excess (11β-HSD2 deficiency, liquorice) Low Low Spironolactone / stop liquorice
Glucocorticoid-remediable aldosteronism Low High Low-dose dexamethasone

Complications across the spectrum

  • Distal RTA: nephrocalcinosis, recurrent calcium phosphate stones, CKD, hypokalaemic paralysis/arrhythmia, growth retardation, osteomalacia.
  • Proximal RTA / Fanconi: rickets/osteomalacia, growth failure, hypophosphataemia.
  • Type IV: dangerous hyperkalaemia, especially when ACEi/ARB or potassium-sparing diuretics are added.
  • Bartter/Gitelman: chronic hypokalaemia (arrhythmia), volume depletion, tetany (Gitelman), nephrocalcinosis (Bartter), chondrocalcinosis (Gitelman).
  • Liddle: end-organ damage from sustained hypertension; severe hypokalaemia.

Key differentials

  • Diarrhoea / GI bicarbonate loss — normal-anion-gap acidosis but negative UAG (vs positive in RTA).
  • Surreptitious diuretic/laxative abuse or vomiting — mimics Gitelman/Bartter biochemically; urine chloride and a diuretic screen help (vomiting → low urine Cl⁻; diuretic abuse → high urine Cl⁻ intermittently).
  • Primary hyperaldosteronism — hypertensive hypokalaemic alkalosis but high aldosterone (vs low in Liddle).
  • DKA/lactic acidosis — high anion gap, distinguishing them from RTA at the very first step.

Recently asked / exam angle

  • "Patient with Sjögren syndrome, hypokalaemia, urine pH 6.5, positive urine anion gap" → distal (type I) RTA.
  • "Glycosuria with normal blood sugar + phosphaturia + aminoaciduria" → proximal RTA / Fanconi; in a child suspect cystinosis, in an adult on HIV therapy suspect tenofovir, in an elderly patient with bone pain suspect multiple myeloma.
  • "Diabetic with mild hyperchloraemic acidosis and hyperkalaemia, urine pH < 5.5" → type IV RTA (hyporeninaemic hypoaldosteronism).
  • "Negative urine anion gap in a child with diarrhoea" → appropriate renal NH₄⁺ excretion, not RTA.
  • "Hypokalaemic alkalosis, normal BP, low urine calcium, low magnesium, adolescent" → Gitelman; if high urine calcium + nephrocalcinosis in a neonate → Bartter.
  • "Young hypertensive, hypokalaemic alkalosis, low renin AND low aldosterone, not responding to spironolactone, responds to amiloride" → Liddle syndrome.
  • Drug pairings tested: amphotericin B → distal RTA; acetazolamide / tenofovir → proximal RTA; trimethoprim / spironolactone / NSAIDs → type IV.
  • Treatment pairings: distal/proximal RTA → potassium citrate; proximal RTA additionally responds to thiazides; Liddle → amiloride; neonatal Bartter → indomethacin.

Rapid revision

  1. RTA = normal anion gap (hyperchloraemic) metabolic acidosis with preserved GFR.
  2. Type I (distal): hypokalaemia, urine pH > 5.5, nephrocalcinosis + calcium phosphate stones; causes — Sjögren, amphotericin B.
  3. Type II (proximal): bicarbonaturia, Fanconi syndrome, needs high-dose alkali; causes — cystinosis, tenofovir, myeloma, acetazolamide.
  4. Type IV: the only hyperkalaemic RTA, urine pH < 5.5, due to hypoaldosteronism; commonest cause diabetic nephropathy.
  5. No clinically meaningful "type III" RTA.
  6. Urine anion gap: negative → diarrhoea/GI loss ("neGUTive"); positive → RTA.
  7. Confirmatory for distal RTA = ammonium chloride loading test (urine fails to acidify < 5.5).
  8. Bartter = loop-diuretic mimic, hypercalciuria, nephrocalcinosis, neonatal onset.
  9. Gitelman = thiazide mimic, hypocalciuria + hypomagnesaemia, adolescent/adult, milder.
  10. Bartter and Gitelman both have normal/low BP with high renin and aldosterone.
  11. Liddle = ENaC gain-of-function: hypertension + hypokalaemic alkalosis + low renin & low aldosterone; treat with amiloride (spironolactone fails).
  12. Drug of choice for alkali therapy in RTA = potassium citrate (corrects acidosis, hypokalaemia, and reduces stones).